Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1730 - Comparisons of tumor-infiltrating lymphocytes and 21-gene recurrence score in ER-positive/HER2-negative breast cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Sung Gwe Ahn

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

S.G. Ahn1, Y.J. Cha2, C. Yoon1, S.J. Bae1, J. Kim3, J. Jeong1

Author affiliations

  • 1 Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, 135-720 - Seoul/KR
  • 2 Pathology, Gangnam Severance Hospital, 06229 - Seoul/KR
  • 3 Surgery, Kangnam Mizmedi Hospital, 06229 - Seoul/KR
More

Resources

Abstract 1730

Background

Recent meta-analysis showed that tumors with high tumor-infiltrating lymphocyte (TIL) have a higher probability of pathologic complete response even in Luminal/HER2-negative breast cancer. Also, the 21-gene recurrence score (RS) predicts the clinical benefit of chemotherapy for ER-positive/HER2-negative women. We compared two markers in those cancer.

Methods

In ER-positive/HER2-negative patients treated with primary surgery, the RS (Oncotype DX® Breast Cancer Assay; Genomic Health, Inc., USA) was obtained. We evaluated TIL in H&E slides of surgical specimens by standardized methodology proposed by the international TIL-working group. In 198 women, the percentage of stromal TIL was successfully assessed. In accordance with the recent meta-analysis, the degree of TILs were categorized as high ( > =60%), intermediate (11-59%), and low ( 

Results

Ninety-seven (49.0%), 88 (44.4%), and 13 patients (6.6%) had low, intermediate, and high TILs, respectively. There is a significant but weak correlation between continuous RS and continuous TIL (Pearson’s R = 0.201, P = 0.004). The average of continuous RS was significantly highest in the high TIL tumors (17.8±10.7 in low TIL, 19.4±8.7 in intermediate TIL, and 26.2±8.2 in high TIL; P = 0.014). Whereas the average of continuous TILs was compared according to categorized RS, it was significantly higher in the intermediate RS or the high RS tumors (15.4±13.2 in low RS, 26.6±13.6 in intermediate RS, and 19.8±19.2 in high RS; P 

Conclusions

We found that tumors with high TIL tend to have a higher RS in ER-positive/HER2-negative breast cancer. We also noted that the rate of high-TIL tumors was significantly higher in the intermediate-RS tumors as well as in the high-RS tumors. Clinically, our findings suggest that TIL count might be referred in decision-making of chemotherapy in the intermediate RS-patients.Table:

194P

Low or Intermediate TILHigh TILP-vlaue
Low RS (N = 98)97 (99%)1 (1%)0.007
Intermediate RS (N = 80)70 (88%)10 (12%)
High RS (N = 20)18 (90%)2 (10%)

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

This research was supported by the Basic Science Research Program through the NRF, funded by the Ministry of Science, ICT, & Future Planning (NRF-2015R1C1A1A02037104), and grant from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (1520120).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.